logo image

Moclobemide information from DrugsUpdate  

See Available Brands of Moclobemide in India

P - Caution when used during pregnancy
L - Caution when used during lactation
FI - Food *

Moclobemide (sold as Aurorix, Manerix) is a drug primarily used to treat depression and social anxiety. Although clinical trials with the medicine began in 1977, it is not approved for use in the United States. It is produced by affiliates of the Hoffmann-La Roche pharmaceutical company.

Pharmacodynamics

Pharmacokinetics

Moclobemide acts by reversible inhibition of the isoenzyme monoamine oxidase type A and thus preferentially increasing the availability of the neurotransmitters serotonin, epinephrine, and norepinephrine.

Absorption
Readily and 98% from the GI tract; peak plasma concentrations within 1 hour (oral).

Distribution

50% bound to plasma proteins; enters breast milk.

Metabolism

Extensively hepatic by oxidative reactions.

Excretion
Via urine as metabolites (95%); 1-2 hours (elimination half-life).

Moclobemide Indications / Moclobemide Uses

Information Not Available

Moclobemide Adverse Reactions / Moclobemide Side Effects

Tachycardia, hypotension, dizziness, headache, drowsiness, sleep disturbances, agitation, nervousness, sedation, somnolence, anxiety, increased appetite, xerostomia, nausea, constipation, abdominal pain, diarrhoea, vomiting, weakness, blurred vision, increased sweating, increased transaminases, elevated creatine kinase (CK) and creatine phosphokinase (CPK).

Potentially Fatal: Hypertensive crisis.

Precautions

Information Not Available


 

Special Precautions

Excited or agitated patients; bipolar disorders; hepatic impairment; thyrotoxicosis. Early antidepressant therapy; close monitoring particularly during periods of dosage adjustments. May impair ability to drive or operate machinery. Pregnancy and lactation. Withdrawal should be gradual.

Other Drug Interactions

Increased plasma concentrations with cimetidine. Behavioural and neurologic syndromes with tryptophan. Excessive sedation and acute hypotension with CNS depressants (opiates or others analgesics, barbiturates or other sedatives, anaesthetics or alcohol). Marked hypotensive effects with diuretics and hypotensive agents. Worsening of depression and/or suicidality with antidepressants.

Potentially Fatal: Serotonin syndrome with sympathomimetic agents (e.g. amphetamines, dopamine, epinephrine, norepinephrine, methylphenidate) or related substances (e.g. methyldopa, levodopa, L-tryptophan, L-tyrosine, phenylalanine), MAOI, meperidine, TCA, serotonergic drugs (SSRI). Do not use until at least a wk after discontinuation of an SSRI or SSRI-related antidepressant, a TCA or TCA-related, or a non-selective MAOI.

Other Interactions

Food Interaction
Avoid large amounts of tyramine-rich food (e.g. certain cheeses, tofu, soybeans, fish, lima beans, coffee) as the pressor effect of tyramine may be potentiated. Avoid ginkgo (may lead to MAOI toxicity). Avoid ephedra, yohimbe (can cause hypertension). Avoid kava (may increase CNS depression).

Dosage

Oral
Depression

Adult: Initially, 300 mg daily in divided doses; increase up to 600 mg daily according to patient's response. Maintenance: 150 mg daily.
Hepatic impairment: Reduce to ½ or 1/3 of recommended dose.

Oral
Social anxiety disorder

Adult: Initially, 300 mg daily; increase to 600 mg daily in 2 divided doses after 3 days. Continue for 8-12 weeks.
Hepatic impairment: Reduce to ½ or 1/3 of recommended dose.

Food(before/after)

Should be taken with food. (Take immediately after meals.)

List of Contraindications

Moclobemide and Pregnancy

Caution when used during pregnancy

Moclobemide and Lactation

Caution when used during lactation

Moclobemide and Children

Information Not Available


 

Moclobemide and Geriatic

Information Not Available


 

Moclobemide and Other Contraindications

Acute confusional states and phaeochromocytoma.

Storage

Oral
Store at 15-30°C.

Lab interference

Oral
Store at 15-30°C.

Moclobemide brands in India:

Morex Rimarex Trima

© 2011-2018 DrugsUpdate.com. Disclaimer | Site Map

Feedback